Cargando…

Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection

Patients with Hantavirus-caused epidemic hemorrhagic fever (EHF) are at risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is currently no validated EHF/SARS-CoV-2 strategy. Several studies have recently shown Puerarin, a natural product, has potent anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Weizheng, Li, Xiushen, Wang, Hao, Nie, Kechao, Meng, Qingxue, He, Junli, Zheng, Chunfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161725/ https://www.ncbi.nlm.nih.gov/pubmed/35663983 http://dx.doi.org/10.3389/fimmu.2022.892350

Ejemplares similares

Puerarin: A Potential Therapeutic for Colon Adenocarcinoma (COAD) Patients Suffering From SARS-CoV-2 Infection
por: Liang, Weizheng, et al.
Publicado: (2022)

The Roles of Adipose Tissue Macrophages in Human Disease
por: Liang, Weizheng, et al.
Publicado: (2022)

Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets
por: Zheng, Zhihua, et al.
Publicado: (2023)

Exploration of the common gene and potential molecular mechanisms between Herpes simplex virus 1 infection and Alzheimer's disease
por: Liang, Weizheng, et al.
Publicado: (2022)

Exploration of the Shared Gene and Molecular Mechanisms Between Endometriosis and Recurrent Pregnancy Loss
por: Ye, Zhuang, et al.
Publicado: (2022)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19
por: Li, Xiushen, et al.
Publicado: (2022)

Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses
por: Cao, Yingying, et al.
Publicado: (2021)

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
por: Liang, Yanwen, et al.
Publicado: (2020)

Editorial: New therapeutic approaches for SARS-CoV-2/COVID-19
por: Rodriguez-Morales, Alfonso J., et al.
Publicado: (2023)

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
por: Xiao, Xia, et al.
Publicado: (2020)

Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
por: Di Vito, Clara, et al.
Publicado: (2022)

Cannabidiol and SARS-CoV-2 Infection
por: Vallée, Alexandre
Publicado: (2022)

Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
por: Zhu, Ling, et al.
Publicado: (2020)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
por: Wu, Jiajing, et al.
Publicado: (2021)

Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020)

Taking on SARS-CoV-2
por: Kučan Brlić, Paola, et al.
Publicado: (2022)

Immunomodulatory Drugs in the Management of SARS-CoV-2
por: Burrage, Daniel R., et al.
Publicado: (2020)

Immunity to SARS-CoV-2: Lessons Learned
por: Fergie, Jaime, et al.
Publicado: (2021)

CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021)

The Spike of SARS-CoV-2: Uniqueness and Applications
por: Kumavath, Ranjith, et al.
Publicado: (2021)

SARS-CoV-2 and the host-immune response
por: Maison, David P., et al.
Publicado: (2023)

Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues
por: Subbarayan, Karthikeyan, et al.
Publicado: (2021)

SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics
por: Chatterjee, Bhaswati, et al.
Publicado: (2022)

Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
por: Santos, Susana, et al.
Publicado: (2022)

SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
por: Schmidt, Katja G., et al.
Publicado: (2021)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
por: Mooij, Petra, et al.
Publicado: (2022)

Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections
por: Qassim, Suelen H., et al.
Publicado: (2022)

Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection
por: Shaw, Jane Alexandra, et al.
Publicado: (2023)

SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
por: Khalaf, Khalil, et al.
Publicado: (2020)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

SARS-CoV-2 Variants, Vaccines, and Host Immunity
por: Mistry, Priyal, et al.
Publicado: (2022)

Adaptive Immune Responses and Immunity to SARS-CoV-2
por: Primorac, Dragan, et al.
Publicado: (2022)

Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection
por: Shah, Taif, et al.
Publicado: (2022)

Macrophage Boolean networks in the time of SARS-CoV-2
por: de León, Ugo Avila-Ponce, et al.
Publicado: (2022)

Omicron variants of SARS-CoV-2 and long COVID
por: Yang, Chengliang, et al.
Publicado: (2022)

Defending against SARS-CoV-2: The T cell perspective
por: Almendro-Vázquez, Patricia, et al.
Publicado: (2023)

Adherence to Sars-CoV2 vaccination in hematological patients
por: Narinx, Justine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sbchs0hb071d3cdjk8fm0mhnrr